Plain-English translation of NCT07221851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new growth hormone medication called lonapegsomatropin, given once per week by injection, compared to the standard daily growth hormone injection called somatropin. The study wants to see if the weekly injection works just as well as the daily one for helping children and teenagers with short stature grow taller. About 186 children will participate across seven countries.
Many children with short stature need growth hormone treatment, but daily injections can be difficult for families to manage. This medication is designed to work just as well with only one injection per week instead of seven, which could make treatment easier and less burdensome for children and their families.
You likely qualify if…
You likely don't qualify if…
You will receive growth hormone injections under your skin either once per week for 2 years, or once daily for 1 year followed by once-weekly injections for 1 year. You will have regular visits to a clinic where doctors will measure your height, check your health, and do blood tests to see how well the treatment is working. The entire trial lasts about 2 years.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States